A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
While the research behind GLP1 has never been under question, many people report difficulty finding primary physicians who were willing to recommend GLP1s as a first stop in a weight management journey.
While a lack of evidence is rarely an issue, the objections to GLP1 as the first approach in getting body weight under control have been varied:
- Taking the "easy way" is sometimes seen as reducing discipline
- Hesitance around side effects were as of yet under-explored
- Affordability and Insurance coverage issues
Without commenting on the validity of such objections, the results that have been generated by GLP1 Receptor Agonists have spoken for themselves – GLP1 is now recommended by the American College of Cardiology as a first-approach for weight management.
